Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05288959
Other study ID # 2014p002652
Secondary ID R01NS126337-01 (
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date March 31, 2027

Study information

Verified date March 2022
Source Massachusetts General Hospital
Contact Aapo Nummenmaa, PhD
Phone 617-726-2000
Email nummenma@mgh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study of normal brain physiology in healthy human volunteers. The study aims to understand the physiology of connectivity between brain regions. To reach this aim, it delivers single-pulse transcranial magnetic stimulation (spTMS) to one or two brain areas at a time while electroencephalography (EEG) is measured. When only one brain area is stimulated (uni-focal TMS), the goal is to record how many milliseconds it takes for the activity to spread from the stimulated area to other brain regions (conduction delay). When two brain areas are stimulated (bi-focal TMS), the TMS pulses are separated by a short millisecond-level time interval ("asynchrony") in a so-called paired associative stimulation (PAS) design. The central hypothesis is that PAS may increase or decrease connectivity between the stimulated areas depending on the asynchrony value. All techniques in the study are non-invasive and considered safe.


Description:

The goal of the study is to illuminate the physiology of inter-regional connectivity in the human brain. Participants are healthy adult volunteers without disorders or medications influencing brain function (N=80). During uni-focal TMS, only one brain area is stimulated at a time, and the conduction delays and connectivity strengths between the stimulated brain area and other brain regions are quantified with source-resolved EEG. During the bi-focal TMS sessions, a range of negative and positive PAS asynchronies (from minus 50 to + 50 ms relative to the conduction delays) will be tested in separate sessions, and the within-session connectivity changes from PAS are estimated by applying uni-focal TMS before and after PAS. The targeted brain areas include the primary motor cortices in the left and right hemisphere as well as areas outside the primary motor cortices. All techniques included in the study are non-invasive and considered safe: TMS, EEG, electromyography (EMG), magnetic resonance imaging (MRI), diffusion MRI (dMRI), functional MRI (fMRI), and behavioral measures. The TMS parameters in this study are considered safe, as only single or pairs of TMS pulses are delivered.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date March 31, 2027
Est. primary completion date March 31, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Healthy - Normal hearing and (corrected) vision - Able to understand and give informed consent Exclusion Criteria: - Metal in the body (rods, plates, screws, shrapnel, dentures, IUD) - Metallic particles in the eye - Surgical clips in the head or previous neurosurgery - Cardiac pacemaker or pacemaker wires - Neurostimulators - Implanted pumps - Any magnetic particles in the body - Cochlear implants - Prosthetic heart valves - Epilepsy or any other type of seizure history - Significant claustrophobia - Meniere's disease - Pregnancy or breast-feeding - Diagnoses or medications (neurological or psychiatric) influencing brain function - History of, or current, substance abuse - History of developmental disorders (e.g., dyslexia) - Failure to perform the behavioral tasks - Prisoners

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Session 2: Single-pulse TMS (spTMS)
Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
Sessions 3 - 5: Paired associative stimulation (PAS)
During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.

Locations

Country Name City State
United States Mass General Brigham Charlestown Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cortico-cortical evoked potential (ccEP) latencies EEG/EMG are recorded with a 64/16-channel TMS-compatible device (NeurOne, Bittium, Kuopio, Finland) while spTMS is delivered. Thereafter, the sensor-space evoked potentials (EPs) undergo EEG source analysis to produce source-space ccEPs. For sessions with uni-focal TMS, the ccEPs latencies are used for determining the inter-regional conduction delays. Recorded in the uni-focal TMS session, on average on Day 14 (Session 2). The ccEPs are measured once for each TMS location and intensity.
Primary Change in cortico-cortical evoked potential (ccEP) amplitudes EEG/EMG are recorded with a 64/16-channel TMS-compatible device (NeurOne, Bittium, Kuopio, Finland) while spTMS is delivered. Thereafter, the sensor-space evoked potentials (EPs) undergo EEG source analysis to produce source-space ccEPs. For sessions with bi-focal TMS (PAS), the ccEPs amplitudes are used for determining the within-session effects of PAS by measuring the change in amplitudes before versus after the PAS modulation. Recorded in each bi-focal TMS (PAS) session, on average on Days 28, 35, and 42 (Sessions 3, 4, and 5, respectively).
Secondary MRI structural connectivity Diffusion MRI will be used to assess structural connectivity strengths between the stimulated areas in bi-focal TMS (PAS). The structural connectivity strengths will be compared with EEG-derived connectivity strengths. Once on Day 1 (Session 1, before first TMS session).
Secondary MRI functional connectivity Resting-state fMRI will be used to assess functional connectivity strengths between the stimulated areas in bi-focal TMS (PAS). The functional connectivity strengths will be compared with EEG-derived connectivity strengths. Once on Day 1 (Session 1, before first TMS session).
Secondary Change in bimanual coordination task (BCT) performance Behavioral measures of inter-hemispheric communication between the left and right motor cortices will be recorded with the BCT. Change is measured by comparing performance before vs. after the PAS modulation. Recorded in each bi-focal TMS (PAS) session, on average on Days 28, 35, and 42 (Sessions 3, 4, and 5, respectively).
Secondary Change in resting-state EEG (rs-EEG) connectivity using phase slope index (PSI) EEG/EMG are recorded with a 64/16-channel TMS-compatible device (NeurOne, Bittium, Kuopio, Finland) during rest. Thereafter, unaveraged source-space time courses are extracted from the sensor-space EEG using source analysis techniques. The source-space time courses from the stimulated areas are analyzed for signs of connectivity changes by comparing the within-session PSI values before versus after the PAS modulation. Recorded in each bi-focal TMS (PAS) session, on average on Days 28, 35, and 42 (Sessions 3, 4, and 5, respectively).
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1